Prostatectomía radical robot-asistida con preservación del espacio de Retzius: resultados perioperatorios y de continencia inmediata en una serie inicial / Retzius-sparing robot-assisted radical prostatectomy: Perioperative and immediate continence outcomes of an initial series

OBJETIVO: Los objetivos de este trabajo son presentar los resultados perioperatorios, de continencia inmediata y oncológicos iniciales en una serie de 25 pacientes con cáncer de próstata tratados con prostatectomía radical robot-asistida con preservación del espacio de Retzius. MATERIAL Y MÉTODOS: Analizamos retrospectivamente una serie de 25 pacientes tratados con prostatectomía radical robótica con preservación del espacio de Retzius por cáncer de próstata cT1-T2b entre 2018-2019. Se describen las 5 etapas de la cirugía. Efectuamos una estadística descriptiva de nuestra serie inicial y sus resultados en términos de continencia inmediata, definida como el uso de 0 compresas/pañales o 1 por seguridad/24 horas en la primera semana tras retirada de la sonda. RESULTADOS: Mediana de seguimiento, 6 meses (3-18). Mediana de PSA, 6,1 ng/ml (4-14,3). Todas las cirugías se realizan por vía posterior e intrafascial con preservación neurovascular bilateral en el 84% de los casos. El 28% tienen un margen quirúrgico afectado siendo el ápex la zona de afectación más frecuente. Complicaciones quirúrgicas: 1 (4%) paciente requirió transfusión de hemoderivados en el postoperatorio inmediato. Mediana de estancia hospitalaria 48 horas. Resultados funcionales: el 80% tiene continencia inmediata. El 80% de los continentes no requiere el uso de ningún pañal/compresa de seguridad. Resultados oncológicos: el 84% están libres de progresión bioquímica con una mediana de seguimiento de 6 meses. CONCLUSIONES: Los resultados funcionales iniciales en términos de continencia inmediata son muy satisfactorios en pacientes intervenidos de prostatectomía radical robótica con preservación del espacio de Retzius sin impacto negativo en el pronóstico

OBJECTIVE: The objective of this work is to present initial perioperative, immediate continence and oncological results in a series of 25 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. MATERIAL AND METHODS: We retrospectively analyzed a series of 25 patients treated with Retzius-sparing robot-assisted radical prostatectomy for cT1-T2b prostate cancer between 2018-2019. The 5 stages of surgery are described. We make a descriptive statistic of our initial series and its outcomes in terms of immediate continence, defined as the use of 0 pad/diapers or 1 safety pad/diaper every 24 hours, one week after catheter removal. RESULTS: Median follow-up, 6 months (3-18). Median PSA, 6.1 ng/ml (4-14.3). All surgeries were performed through a posterior intrafascial approach, and bilateral nerve-sparing was carried out in 84% of the cases. Affected surgical margins were present in 28%, being the apex the most frequent site of affectation. Surgical complications: 1 (4%) patient required transfusion of blood products in the immediate postoperative period. Mean hospital stay was 48 hours. Functional outcomes: 80% of the patients present immediate continence. 80% of continent patients do not require the use of any safety pads/diapers. Oncological outcomes: 84% are free of biochemical-progression in a median follow-up of 6 months. CONCLUSIONS: Initial functional results in terms of immediate continence are very satisfactory in patients who have undergone Retzius-sparing robot-assisted radical prostatectomy without negative impact on prognosis

Retzius-sparing robot-assisted radical prostatectomy: Perioperative and immediate continence outcomes of an initial series. / Prostatectomía radical robot-asistida con preservación del espacio de Retzius: resultados perioperatorios y de continencia inmediata en una serie inicial.

OBJECTIVE: The objective of this work is to present initial perioperative, immediate continence and oncological results in a series of 25 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. MATERIAL AND METHODS: We retrospectively analyzed a series of 25 patients treated with Retzius-sparing robot-assisted radical prostatectomy for cT1-T2b prostate cancer between 2018-2019. The 5 stages of surgery are described. We make a descriptive statistic of our initial series and its outcomes in terms of immediate continence, defined as the use of 0 pad/diapers or 1 safety pad/diaper every 24 hours, one week after catheter removal. RESULTS: Median follow-up, 6 months (3-18). Median PSA, 6.1 ng/ml (4-14.3). All surgeries were performed through a posterior intrafascial approach, and bilateral nerve-sparing was carried out in 84% of the cases. Affected surgical margins were present in 28%, being the apex the most frequent site of affectation. Surgical complications: 1 (4%) patient required transfusion of blood products in the immediate postoperative period. Mean hospital stay was 48 hours. Functional outcomes: 80% of the patients present immediate continence. 80% of continent patients do not require the use of any safety pads/diapers. Oncological outcomes: 84% are free of biochemical-progression in a median follow-up of 6 months. CONCLUSIONS: Initial functional results in terms of immediate continence are very satisfactory in patients who have undergone Retzius-sparing robot-assisted radical prostatectomy without negative impact on prognosis.

Dolor y simulación: reto diagnóstico y terapéutico / Pain and simulation: diagnostic and therapeutic challenges

No disponible

Modelos de riesgo en pacientes con carcinoma de células renales localizado / Risk models for patients with localised renal cell carcinoma

Introducción: Realizamos un análisis retrospectivo de nuestra serie para evaluar los factores influyentes en la supervivencia libre de enfermedad (SLE) y en la supervivencia cáncer-específica (SCE) en pacientes con carcinoma de células renales (CCR) localizado y realizamos unos grupos de riesgo propios. Material y métodos: Entre enero de 1990 y diciembre de 2012 fueron operados 596 pacientes con CCR localizado (tanto de células claras como papilares o cromófobos). Se analizan las variables clinicopatológicas influyentes en la SLE y en la SCE mediante modelos de regresión de Cox y con ellas se diseñan grupos de riesgo de SLE y de SCE. Resultados: La mediana de seguimiento de la serie es de 5,96 años. Al final del estudio 112 pacientes (18,8%) evidenciaron recidiva de la enfermedad, siendo la SLE del 82%, 77% y 72% a 5, 10 y 15 años respectivamente. Los factores de influencia independiente en la SLE en el estudio multivariado fueron: grado de Furhman III-IV, hematuria, afectación vascular linfática, la presencia de necrosis tumoral y el estadio patológico pT3-pT4. Por otro lado, al final del estudio 57 pacientes (9,6%) fallecieron a causa del cáncer renal, siendo la SCE del 92%, 86% y 83% a 5, 10 y 15 años respectivamente. Los factores de influencia independiente en la SCE en el estudio multivariado fueron: Grado de Furhman III-IV, afectación de la grasa perirrenal y la presencia de necrosis tumoral. Conclusiones: Además del estadio patológico pT3-pT4 en pacientes con CCR localizado son importantes otros factores, como la presencia de hematuria y la afectación vascular linfática para la SLE; y especialmente relevantes el grado de Furhman III-IV y la presencia de necrosis tumoral tanto para la SLE como para la SCE

Introduction: We conducted a retrospective analysis of our series to assess the factors that influenced disease-free survival (DFS) and cancer-specific survival (CSS) for patients with localised renal cell carcinoma (RCC). We also created our own risk groups. Material and methods: Between January 1990 and December 2012, 596 patients underwent surgery for localised RCC (clear cell, papillary or chromophobe). Using Cox regression models, we analysed the clinical-pathological variables that influenced DFS and CSS and designed risk groups for DFS and CSS with the variables. Results: The median follow-up for the series was 5.96 years. By the end of the study, 112 patients (18.8%) had a recurrence of the disease, with DFS rates of 82%, 77% and 72% at 5, 10 and 15 years, respectively. The independent factors that influenced DFS in the multivariate study were the following: A Furhman grade of 3-4, haematuria, lymphocytic or vascular invasion, the presence of tumour necrosis and a disease stage pT3-pT4. Furthermore, by the end of the study, 57 patients (9.6%) died due to renal cancer, with CSS rates of 92%, 86% and 83% at 5, 10 and 15 years, respectively. The independent factors that influenced CSS in the multivariate study were the following: A Furhman grade of 3-4, perinephric fat invasion and the presence of tumour necrosis. Conclusions: Factors in addition to the disease stage pT3-pT4 in patients with localised RCC are important, such as the presence of haematuria and lymphocytic or vascular invasion for DFS. A Furhman grade of 3-4 and the presence of tumour necrosis are especially relevant for DFS and CSS

Predicción de efectividad de litotricia extracorpórea por ondas de choque en cálculos del tracto urinario. Grupos de riesgo para precisar retratamiento / Predicting the effectiveness of extracorporeal shock wave lithotripsy on urinary tract stones. Risk groups for accurate retreatment

Introducción: La litotricia extracorpórea por ondas de choque (LEOC) es un tratamiento no invasivo, seguro y efectivo para las litiasis del tracto urinario cuya efectividad varía según la localización y el tamaño del cálculo, entre otros factores; en ocasiones es necesario realizar varias sesiones. El objetivo es tratar de predecir el éxito o fracaso conociendo previamente las variables influyentes. Material y métodos: Analizamos a 211 pacientes con TAC previa entre aquellos tratados mediante LEOC entre los años 2010 y 2014. Se estudian las variables influyentes en la necesidad de retratamiento utilizando modelos de regresión logística binaria (estudio uni- y multivariado): densidad máxima, diámetro máximo, área, localización, desintegración y distancia del panículo adiposo. Con las variables influyentes se ha diseñado un modelo de riesgo valorando con regresión logística todas las posibles combinaciones (IBM SPSS versión 20.0). Resultados: Las variables de influencia independiente en la necesidad de retratamiento son: densidad máxima >864UH, diámetro máximo >7,5mm y localización pielocalicial. Utilizando estas variables, el mejor modelo incluye 3grupos de riesgo con probabilidades de necesitar retratamiento significativamente diferentes: grupo 1-bajo riesgo (0 variables) con 20,2%, grupo 2-riesgo intermedio (1-2 variables) con 49,2% y grupo 3-alto riesgo (3 variables) con 62,5%. Conclusiones: La densidad, el diámetro máximo y la localización pielocalicial del cálculo son factores determinantes en la efectividad del tratamiento con LEOC. Con estas variables, que se pueden obtener antes de la decisión terapéutica, el modelo de riesgo diseñado permite una aproximación precisa de cara a elegir el tratamiento más adecuado para cada caso en particular

Introduction: Extracorporeal shock wave lithotripsy (ESWL) is a non-invasive, safe and effective treatment for urinary tract lithiasis. Its effectiveness varies depending on the location and size of the stones as well as other factors; several sessions are occasionally required. The objective is to attempt to predict its success or failure, when the influential variables are known beforehand. Material and methods: We analysed 211 patients who had had previous CT scans and were treated with ESWL between 2010 and 2014. The influential variables in requiring retreatment were studied using binary logistic regression models (univariate and multivariate analysis): maximum density, maximum diameter, area, location, disintegration and distance from the adipose panniculus. With the influential variables, a risk model was designed by assessing all possible combinations with logistic regression (version 20.0 IBM SPSS). Results: The independent influential variables on the need for retreatment are: maximum density > 864 HU, maximum diameter > 7.5 mm and pyelocaliceal location. Using these variables, the best model includes 3risk groups with a probability of requiring significantly different retreatment: group 1-low risk (0 variables) with 20.2%; group 2-intermediate risk (1-2 variables) with 49.2%; and group 3-high risk (3 variables) with 62.5%. Conclusions: The density, maximum diameter and pyelocaliceal location of the stones are determinant factors in terms of the effectiveness of treatment with ESWL. Using these variables, which can be obtained in advance of deciding on a treatment, the designed risk model provides a precise approach in choosing the most appropriate treatment for each particular case

QSPR studies on the photoinduced-fluorescence behaviour of pharmaceuticals and pesticides.

Fluorimetric analysis is still a growing line of research in the determination of a wide range of organic compounds, including pharmaceuticals and pesticides, which makes necessary the development of new strategies aimed at improving the performance of fluorescence determinations as well as the sensitivity and, especially, the selectivity of the newly developed analytical methods. In this paper are presented applications of a useful and growing tool suitable for fostering and improving research in the analytical field. Experimental screening, molecular connectivity and discriminant analysis are applied to organic compounds to predict their fluorescent behaviour after their photodegradation by UV irradiation in a continuous flow manifold (multicommutation flow assembly). The screening was based on online fluorimetric measurement and comprised pre-selected compounds with different molecular structures (pharmaceuticals and some pesticides with known 'native' fluorescent behaviour) to study their changes in fluorescent behaviour after UV irradiation. Theoretical predictions agree with the results from the experimental screening and could be used to develop selective analytical methods, as well as helping to reduce the need for expensive, time-consuming and trial-and-error screening procedures.

Risk models for patients with localised renal cell carcinoma. / Modelos de riesgo en pacientes con carcinoma de células renales localizado.

INTRODUCTION: We conducted a retrospective analysis of our series to assess the factors that influenced disease-free survival (DFS) and cancer-specific survival (CSS) for patients with localised renal cell carcinoma (RCC). We also created our own risk groups. MATERIAL AND METHODS: Between January 1990 and December 2012, 596 patients underwent surgery for localised RCC (clear cell, papillary or chromophobe). Using Cox regression models, we analysed the clinical-pathological variables that influenced DFS and CSS and designed risk groups for DFS and CSS with the variables. RESULTS: The median follow-up for the series was 5.96 years. By the end of the study, 112 patients (18.8%) had a recurrence of the disease, with DFS rates of 82%, 77% and 72% at 5, 10 and 15 years, respectively. The independent factors that influenced DFS in the multivariate study were the following: A Furhman grade of 3-4, haematuria, lymphocytic or vascular invasion, the presence of tumour necrosis and a disease stage pT3-pT4. Furthermore, by the end of the study, 57 patients (9.6%) died due to renal cancer, with CSS rates of 92%, 86% and 83% at 5, 10 and 15 years, respectively. The independent factors that influenced CSS in the multivariate study were the following: A Furhman grade of 3-4, perinephric fat invasion and the presence of tumour necrosis. CONCLUSIONS: Factors in addition to the disease stage pT3-pT4 in patients with localised RCC are important, such as the presence of haematuria and lymphocytic or vascular invasion for DFS. A Furhman grade of 3-4 and the presence of tumour necrosis are especially relevant for DFS and CSS.

Predicting the effectiveness of extracorporeal shock wave lithotripsy on urinary tract stones. Risk groups for accurate retreatment. / Predicción de efectividad de litotricia extracorpórea por ondas de choque en cálculos del tracto urinario. Grupos de riesgo para precisar retratamiento.

INTRODUCTION: Extracorporeal shock wave lithotripsy (ESWL) is a non-invasive, safe and effective treatment for urinary tract lithiasis. Its effectiveness varies depending on the location and size of the stones as well as other factors; several sessions are occasionally required. The objective is to attempt to predict its success or failure, when the influential variables are known beforehand. MATERIAL AND METHODS: We analysed 211 patients who had had previous CT scans and were treated with ESWL between 2010 and 2014. The influential variables in requiring retreatment were studied using binary logistic regression models (univariate and multivariate analysis): maximum density, maximum diameter, area, location, disintegration and distance from the adipose panniculus. With the influential variables, a risk model was designed by assessing all possible combinations with logistic regression (version 20.0 IBM SPSS). RESULTS: The independent influential variables on the need for retreatment are: maximum density >864HU, maximum diameter >7.5mm and pyelocaliceal location. Using these variables, the best model includes 3risk groups with a probability of requiring significantly different retreatment: group 1-low risk (0 variables) with 20.2%; group 2-intermediate risk (1-2 variables) with 49.2%; and group 3-high risk (3 variables) with 62.5%. CONCLUSIONS: The density, maximum diameter and pyelocaliceal location of the stones are determinant factors in terms of the effectiveness of treatment with ESWL. Using these variables, which can be obtained in advance of deciding on a treatment, the designed risk model provides a precise approach in choosing the most appropriate treatment for each particular case.

Valor pronóstico de la afectación de vesículas seminales en el espécimen de prostatectomía radical / Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens

Objetivo: Estudiar la influencia en términos de pronóstico del hallazgo de afectación de vesícula seminal en pacientes con adenocarcinoma de próstata tratados mediante prostatectomía radical. Material y método: Se revisa una serie de pacientes con afectación de vesícula seminal con adenocarcinoma de próstata clínicamente localizado sometidos a prostatectomía radical entre 1989-2009, con énfasis en sus características clinicopatológicas, la supervivencia libre de progresión bioquímica (SLPB) y la supervivencia específica (SE). Se evalúan las variables influyentes en la SLPB y se diseña un modelo de riesgo. Resultados: Un total de 127 pacientes sobre 1.132 intervenidos (11%) mostraron invasión de vesícula seminal; es decir, fueron pT3b. En el estudio multivariado de toda la serie (modelo de Cox) pT3b influye en la SLPB (HR: 2; IC 95%: 1,4-3,3; p = 0,001). Otros factores influyentes fueron márgenes afectos, PSA inicial, Gleason patológico y presencia de tumor palpable. Los tumores pT3b presentan peores variables clinicopatológicas cuando se comparan con pT2 y pT3a. El 65% ha evidenciado progresión bioquímica. La SLPB es significativamente peor en pT3b (40 ± 4% y 28 ± 4% a 5 y 10 años) que en pT2 y pT3a (p < 0,0001). La SE también es peor en pacientes pT3b (91 ± 2% y 76 ± 4% a 5 y 10 años) (p < 0,0001). Dentro del grupo de pacientes pT3b las variables predictivas son: PSA > 10 ng/ml (HR: 1,9; IC 95%: 1,04-3,6; p = 0,04) y Gleason patológico 8-10 (HR: 2,1; IC 95%: 1,2-3,5; p = 0,03). Se ha diseñado un modelo de riesgo que tiene en cuenta las variables implicadas, que conlleva 2 grupos con diferente SLPB (p = 0,004): a) grupo 1 (0-1 variables). SLPB: 46 ± 7% y 27 ± 8% a 5 y 10 años; y b) grupo 2 (2 variables). SLPB: 14 ± 7% y 5 ± 5% a 5 y 10 años. Conclusión: La afectación de vesícula seminal influye de manera severamente negativa en la SLPB y en la SE. Se diseña un modelo de riesgo con las variables de influencia independiente en la SLPB (Gleason patológico 8-10 y PSA > 10 ng/ml). Este modelo confirma que los tumores pT3b son un grupo heterogéneo, dentro del cual hay un grupo importante de mejor pronóstico cuando se lleva a cabo tratamiento quirúrgico

Objective: To study the influence, in terms of prognosis, of the finding of seminal vesicle involvement in patients with prostate adenocarcinoma treated with radical prostatectomy. Material and method: We reviewed a series of patients with seminal vesicle involvement with clinically localized prostate adenocarcinoma who underwent radical prostatectomy between 1989 and 2009, focusing on their clinical-pathological characteristics, biochemical progression-free survival (BPFS) and specific survival (SS). We assessed the variables that influenced BPFS and designed a risk model. Results: A total of 127 out of 1,132 patients who underwent surgery (11%) presented seminal vesicle invasion (i.e., pT3b). In the multivariate study of the entire series (Cox model), pT3b affects the BPFS (HR: 2; 95% CI: 1.4-3.3; P = .001). Other influential factors were the affected borders, initial prostate-specific antigen levels, pathological Gleason score and the presence of palpated tumor. The pT3b tumors have poorer clinical-pathological variables when compared with pT2 and pT3a tumors. Sixty-five percent of the patients evidenced biochemical progression. The BPFS was significantly poorer for pT3b (40 ± 4% and 28 ± 4% at 5 and 10 years, respectively) than for pT2 and pT3a (P < .0001). The SS was also poorer in patients with pT3b tumors (91 ± 2% and 76 ± 4% at 5 and 10 years, respectively) (P <. 0001). The predictors within the pT3b patient group were: PSA levels > 10 ng/mL (HR: 1.9; 95% CI: 1.04–3.6; P = .04) and pathological Gleason score 8-10 (HR: 2.1; 95% CI: 1.2-3.5; P = .03). We designed a risk model that accounts for the variables involved, which entails 2 groups with different BPFS (P = .004): Group 1 (0-1 variable), with a BPFS of 46 ± 7% and 27 ± 8% at 5 and 10 years, respectively; and Group 2 (2 variables), with a BPFS of 14 ± 7% and 5 ± 5% at 5 and 10 years, respectively. Conclusion: Seminal vesicle involvement severely and negatively affects the BPFS and SS. We designed a risk model with the independent influential variables in BPFS (pathological Gleason score 8-10 and PSA levels >10 ng/mL). This model confirms that pT3b tumors are a heterogeneous group, which includes an important group with better prognosis when surgical treatment is performed

Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.

OBJECTIVE: To study the influence, in terms of prognosis, of the finding of seminal vesicle involvement in patients with prostate adenocarcinoma treated with radical prostatectomy. MATERIAL AND METHOD: We reviewed a series of patients with seminal vesicle involvement with clinically localized prostate adenocarcinoma who underwent radical prostatectomy between 1989 and 2009, focusing on their clinical-pathological characteristics, biochemical progression-free survival (BPFS) and specific survival (SS). We assessed the variables that influenced BPFS and designed a risk model. RESULTS: A total of 127 out of 1,132 patients who underwent surgery (11%) presented seminal vesicle invasion (i.e., pT3b). In the multivariate study of the entire series (Cox model), pT3b affects the BPFS (HR: 2; 95% CI: 1.4-3.3; P=.001). Other influential factors were the affected borders, initial prostate-specific antigen levels, pathological Gleason score and the presence of palpated tumor. The pT3b tumors have poorer clinical-pathological variables when compared with pT2 and pT3a tumors. Sixty-five percent of the patients evidenced biochemical progression. The BPFS was significantly poorer for pT3b (40 ± 4% and 28 ± 4% at 5 and 10 years, respectively) than for pT2 and pT3a (P<.0001). The SS was also poorer in patients with pT3b tumors (91 ± 2% and 76 ± 4% at 5 and 10 years, respectively) (P<.0001). The predictors within the pT3b patient group were: PSA levels >10 ng/mL (HR: 1.9; 95% CI: 1.04-3.6; P=.04) and pathological Gleason score 8-10 (HR: 2.1; 95% CI: 1.2-3.5; P=.03). We designed a risk model that accounts for the variables involved, which entails 2 groups with different BPFS (P=.004): Group 1 (0-1 variable), with a BPFS of 46 ± 7% and 27 ± 8% at 5 and 10 years, respectively; and Group 2 (2 variables), with a BPFS of 14 ± 7% and 5 ± 5% at 5 and 10 years, respectively. CONCLUSION: Seminal vesicle involvement severely and negatively affects the BPFS and SS. We designed a risk model with the independent influential variables in BPFS (pathological Gleason score 8-10 and PSA levels >10 ng/mL). This model confirms that pT3b tumors are a heterogeneous group, which includes an important group with better prognosis when surgical treatment is performed.

Factores influyentes en la respuesta al rescate con radioterapia tras prostatectomía radical / Influential Factors in the Response to Salvage Radiotherapy After Radical Prostatectomy

Objetivo: Analizar en los pacientes prostatectomizados con posterior progresión bioquímica (PB) y tratados con radioterapia de rescate (RTP) los factores influyentes en la respuesta. Material y métodos: Analizamos 313 pacientes con cáncer de próstata pT2/pT3 que reciben tratamiento de rescate por PB (de una serie de 1.310 pacientes operados entre 1989-2012). De los 313 pacientes 159 (50,8%) reciben solo deprivación androgénica (DA), 63 (20,1%) radioterapia (RTP) más DA concomitante y 91 (29,1%) solo RTP, de los cuales 57 (62,6%) mantienen respuesta completa y 34 (37,4%) fracaso del tratamiento. Resultados: Estudio del grupo tratado solo con RTP de rescate: 91 pacientes son tratados con RTP de rescate. Mediana de seguimiento 6,4 años. Mediana hasta progresión 11 meses. La supervivencia libre de progresión bioquímica post-RTP (SLPBPR) es de 68 ± 7% y 30 ± 10% en 5 y 10 años y la mediana de SLPBPR 7,3 años (6,3-8,3). En el análisis multivariado presentan influencia independiente en la respuesta: el PSA inicial (HR: 1,08; IC 95%: 1,01-1,1; p = 0,02) con mejor punto de corte PSA > 20 ng/ml (HR: 13,6; IC 95%: 2,1-86; p = 0,005) y PSA pre-RTP (HR: 1,9; IC 95%: 1,2-3,3 p=0,009), mejor punto de corte PSA preRTP de 0,92 ng/ml (HR: 4,5; IC95% 1,3-15,6; p = 0,01). SLPBPR a 5 años 81 ± 9% frente a 58 ± 9% con PSA inicial < 20 o > 20 ng/ml (p=0,03). SLPBPR a 5 años 93 ± 5% frente a 53 ± 10% según PSA pre-RTP < 0,9 o > 0,9 ng/ml (p = 0,02). Conclusiones: En los pacientes prostatectomizados tratados con RTP de rescate el PSA preoperatorio > 20 ng/ml y el PSA preRTP > 0,92 ng/ml tienen influencia independiente en la respuesta

Objective: To analyze the influential factors in the response in prostatectomized patients with subsequent biochemical relapse (BCR) and treated with salvage radiotherapy (RTP). Material and methods: We analyzed 313 patients with pT2/pT3 prostate cancer who were receiving salvage therapy due to biochemical relapse (from a series of 1,310 radical prostatectomies between 1989-2012). Of the 313 patients; 159 (50.8%) only received androgen deprivation (AD), 63 (20.1%) Radiotherapy (RTP) plus concomitant AD and 91 (29.1%) only RTP. Of these, 57 (62.6%) have maintained complete response and 34 (37.4%) had failure response with post-RTP BCR. Results: Study of the group treated exclusively with salvage RTP. Ninety-one patients were treated with salvage RTP. Median follow-up was 6.4 years and median to recurrence 11 months. Post-RTP biochemical relapse-free survival (PRBRFS) was 68 ± 7% and 30 ± 10% in 5 to 10 years. Median PRBRFS was 7.3 years (6.3-8.3). Initial PSA (HR: 1.08; 95% CI: 1.01-1.1 P = .02) with best PSA cut-off point PSA > 20 ng/ml (HR: 13.6; 95% CI: 2.1-86 P = .005) and PSA pre-RTP (HR: 1.9; 95% CI: 1.2-3.3; P = .009), best PSA cut-off point PSA preRTP 0.92 ng/ml (HR: 4.5; 95% CI: 1.3-15.6; P = .01) showed independent influence in the response in the multivariate study. PRBRFS at 5 years, 81 ± 9% versus 58 ± 9% with initial PSA < 20 or > 20 ng/ml (P = .03). PRBRFS at 5 years, 93 ± 5% versus 53 ± 10% according to PSA pre-RTP < 0.9 or > 0.9 ng/ml (P = .02). Conclusions: In patients treated with salvage RTP after radical prostatectomy, the preoperative PSA > 20 ng/ml and PSA preRTP > 0.92 ng/ml shows an independent influence on the response

Optimización de los grupos de riesgo de D'Amico en prostatectomía radical añadiendo la información de la resonancia nuclear magnética / Optimizing D’Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data

Objetivos: Se pretende mejorar la eficacia predictora de la clasificación de D’Amico con la resonancia nuclear magnética (RNM) de pelvis. Material y métodos: Se estudian 729 pacientes de una serie de 1.310 prostatectomías radicales por cáncer de próstata T1-T2 a quienes se realizó RNM de pelvis de estadificación. Cada paciente fue calificado con RNM de T2; T3a o T3b. Se excluyen los pacientes N (+). Se identifican los factores clínicos influyentes en el tiempo de supervivencia libre de progresión bioquímica (SLPB) (PSA > 0,4 ng/ml) (estudio univariado y multivariado con modelos de Cox). Se intenta mejorar el poder predictivo del modelo de D’Amico (bajo riesgo: T1; Gleason 2-6; PSA < 10 ng/ml; riesgo intermedio: T2 o Gleason 7 o PSA 10-20 ng/ml; alto riesgo: T3 o Gleason 8-10 o PSA > 20 ng/ml). Resultados: Factores clínicos influyentes en SLPB: en el estudio univariado las variables influyentes son Gleason 7 (HR: 1,7); Gleason 8-10 (HR: 2,9); T2 (HR: 1,6); PSA 10-20 (HR: 2); PSA > 20 (HR: 4,3); D’Amico intermedio (HR: 2,1) y alto (HR: 4,8); RNM T3a (HR: 2,3) y RNM T3b (HR: 4,5). En el estudio multivariado solo son influyentes D’Amico riesgo intermedio (HR: 2; IC 95%: 1,2-3,3); D’Amico alto riesgo (HR: 4,1; IC 95%: 2,4-6,8); RNM T3a (HR: 1,9; IC 95%: 1,2-2,9) y RNM T3b (HR: 3,9; IC 95%: 2,5-6,1). Modelo predictivo: utilizando los modelos multivariantes de Cox se valora el peso de cada variable. Se da un valor de 1 a D’Amico de bajo riesgo y a RNM T2; se da valor de 2 a D’Amico de riesgo intermedio y a RNM T3a y valor 3 a D’Amico alto riesgo y RNM T3b. Cada paciente tiene un marcador que oscila entre 2 y 6. El mejor modelo incluye 3 grupos. Grupo 1 (2-3 puntos, HR 1) 494 (67,7%) pacientes; SLPB de 86 ± 2% y 79 ± 2%, 5 y 10 años. Grupo 2 (4 puntos, HR 3) 179 (24,6%) pacientes; SLPB de 60 ± 4% y 54 ± 5%, 5 y 10 años. Grupo 3 (5-6 puntos, HR 9,3) 56 (7,7%) pacientes; SLPB de 29 ± 8% y 19 ± 7%, 5 y 10 años; mediana de SLPB 1,5 años. Conclusión: El modelo D'Amico mejora significativamente la capacidad de predicción de la SLPB utilizando la información de la RNM

Objectives: To improve the predictive efficacy of the D’Amico risk classification system with magnetic resonance imaging (MRI) of the pelvis. Material and methods: We studied 729 patients from a series of 1310 radical prostatectomies for T1-T2 prostate cancer who underwent staging pelvic MRI. Each patient was classified with T2, T3a or T3b MRI, and N (+) patients were excluded. We identified the therapeutic factors that affected the biochemical progression-free survival (BPFS) time (prostate specific antigen [PSA] levels > 0.4 ng/mL) using a univariate and multivariate study with Cox models. We attempted to improve the predictive power of the D’Amico model (low risk: T1; Gleason 2-6; PSA levels < 10 ng/mL; intermediate risk: T2 or Gleason 7 or PSA levels 10-20 ng/mL; high risk: T3 or Gleason 8-10 or PSA levels > 20 ng/mL). Results: In the univariate study, the clinical factors that influenced BPFS were the following: Gleason 7 (HR: 1.7); Gleason 8-10 (HR: 2.9); T2 (HR: 1.6); PSA levels 10-20 (HR: 2); PSA levels > 20 (HR: 4.3); D’Amico intermediate (HR: 2.1) and high (HR: 4.8) risk; T3a MRI (HR: 2.3) and T3b MRI (HR: 4.5). In the multivariate study, the only variables that affected BPFS were the following: D’Amico intermediate risk (HR: 2; 95% CI 1.2-3.3); D’Amico high risk (HR: 4.1; 95% CI 2.4-6.8); T3a MRI (HR: 1.9; 95% CI 1.2-2.9) and T3b MRI (HR: 3.9; 95% CI 2.5-6.1). Predictive model: Using the multivariate Cox models, we assessed the weight of each variable. A value of 1 was given to D’Amico low risk and T2 MRI; a value of 2 was given to D’Amico intermediate risk and T3a MRI and a value 3 was given to D’Amico high risk and T3b MRI. Each patient had a marker that varied between 2 and 6. The best model included 3 groups, as follows: 494 (67.7%) patients in group 1, with a score of 2-3 points (HR, 1), a BPFS of 86% ± 2% and 79% ± 2% at 5 and 10 years, respectively; 179 (24.6%) patients in group 2, with a score of 4 points (HR, 3), a BPFS of 60% ± 4% and 54% ± 5% at 5 and 10 years, respectively; and 56 (7.7%) patients in group 3, with a score of 5-6 points (HR, 9.3), a BPFS of 29% ± 8% and 19% ± 7% at 5 and 10 years, respectively. The median BPFS time was 1.5 years. Conclusion: MRI data significantly improves the predictive capacity of BPFS when using the D’Amico model data

Influential factors in the response to salvage radiotherapy after radical prostatectomy.

OBJECTIVE: To analyze the influential factors in the response in prostatectomized patients with subsequent biochemical relapse (BCR) and treated with salvage radiotherapy (RTP). MATERIAL AND METHODS: We analyzed 313 patients with pT2/pT3 prostate cancer who were receiving salvage therapy due to biochemical relapse (from a series of 1,310 radical prostatectomies between 1989-2012). Of the 313 patients; 159 (50.8%) only received androgen deprivation (AD), 63 (20.1%) Radiotherapy (RTP) plus concomitant AD and 91 (29.1%) only RTP. Of these, 57 (62.6%) have maintained complete response and 34 (37.4%) had failure response with post-RTP BCR. RESULTS: Study of the group treated exclusively with salvage RTP. Ninety-one patients were treated with salvage RTP. Median follow-up was 6.4 years and median to recurrence 11 months. Post-RTP biochemical relapse-free survival (PRBRFS) was 68 ± 7% and 30 ± 10% in 5 to 10 years. Median PRBRFS was 7.3 years (6.3-8.3). Initial PSA (HR: 1.08; 95% CI: 1.01-1.1 P=.02) with best PSA cut-off point PSA>20 ng/ml (HR: 13.6; 95% CI: 2.1-86 P=.005) and PSA pre-RTP (HR: 1.9; 95% CI: 1.2-3.3; P=.009), best PSA cut-off point PSA preRTP 0.92 ng/ml (HR: 4.5; 95% CI: 1.3-15.6; P=.01) showed independent influence in the response in the multivariate study. PRBRFS at 5 years, 81 ± 9% versus 58 ± 9% with initial PSA <20 or >20 ng/ml (P=.03). PRBRFS at 5 years, 93 ± 5% versus 53 ± 10% according to PSA pre-RTP <0.9 or >0.9 ng/ml (P=.02). CONCLUSIONS: In patients treated with salvage RTP after radical prostatectomy, the preoperative PSA>20 ng/ml and PSA preRTP>0.92 ng/ml shows an independent influence on the response.

Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.

OBJECTIVES: To improve the predictive efficacy of the D'Amico risk classification system with magnetic resonance imaging (MRI) of the pelvis. MATERIAL AND METHODS: We studied 729 patients from a series of 1310 radical prostatectomies for T1-T2 prostate cancer who underwent staging pelvic MRI. Each patient was classified with T2, T3a or T3b MRI, and N (+) patients were excluded. We identified the therapeutic factors that affected the biochemical progression-free survival (BPFS) time (prostate specific antigen [PSA] levels>0.4ng/mL) using a univariate and multivariate study with Cox models. We attempted to improve the predictive power of the D'Amico model (low risk: T1; Gleason 2-6; PSA levels<10ng/mL; intermediate risk: T2 or Gleason 7 or PSA levels 10-20ng/mL; high risk: T3 or Gleason 8-10 or PSA levels>20ng/mL). RESULTS: In the univariate study, the clinical factors that influenced BPFS were the following: Gleason 7 (HR: 1.7); Gleason 8-10 (HR: 2.9); T2 (HR: 1.6); PSA levels 10-20 (HR: 2); PSA levels>20 (HR: 4.3); D'Amico intermediate (HR: 2.1) and high (HR: 4.8) risk; T3a MRI (HR: 2.3) and T3b MRI (HR: 4.5). In the multivariate study, the only variables that affected BPFS were the following: D'Amico intermediate risk (HR: 2; 95% CI 1.2-3.3); D'Amico high risk (HR: 4.1; 95% CI 2.4-6.8); T3a MRI (HR: 1.9; 95% CI 1.2-2.9) and T3b MRI (HR: 3.9; 95% CI 2.5-6.1). Predictive model: Using the multivariate Cox models, we assessed the weight of each variable. A value of 1 was given to D'Amico low risk and T2 MRI; a value of 2 was given to D'Amico intermediate risk and T3a MRI and a value 3 was given to D'Amico high risk and T3b MRI. Each patient had a marker that varied between 2 and 6. The best model included 3 groups, as follows: 494 (67.7%) patients in group 1, with a score of 2-3 points (HR, 1), a BPFS of 86%±2% and 79%±2% at 5 and 10 years, respectively; 179 (24.6%) patients in group 2, with a score of 4 points (HR, 3), a BPFS of 60%±4% and 54%±5% at 5 and 10 years, respectively; and 56 (7.7%) patients in group 3, with a score of 5-6 points (HR, 9.3), a BPFS of 29%±8% and 19%±7% at 5 and 10 years, respectively. The median BPFS time was 1.5 years. CONCLUSION: MRI data significantly improves the predictive capacity of BPFS when using the D'Amico model data.

Evolución del tipo de paciente candidato a prostatectomía radical a lo largo de 2 décadas (1989-2009) / Course of the Type of Patient who is Candidate for Radical Prostatectomy Over 2 Decades (1989-2009)

Objetivo: Conocer los cambios que ha experimentado el perfil de paciente candidato a prostatectomía radical a lo largo de las últimas 2 décadas en nuestra institución. Material y métodos: Analizamos retrospectivamente una serie de 1.132 pacientes con cáncer de próstata estadio T1-T2, sometidos a prostatectomía radical durante el periodo 1989-2009. La serie se divide en 5 grupos homogéneos en cuanto al número de pacientes y ordenados cronológicamente. Se emplea la supervivencia libre de progresión bioquímica (SLPB) como criterio pronóstico principal. Resultados: A pesar de los cambios en el diagnóstico y tratamiento de la enfermedad, desde el punto de vista del pronóstico (SLPB) apreciamos 2 grupos diferentes de pacientes: los primeros 250 intervenidos y el resto. El punto de corte cronológico se sitúa en esta serie en 1999. Encontramos diferencias significativas en la mayoría de las variables clínico-patológicas como nivel de PSA al diagnóstico (p < 0,001), porcentaje de tumores palpables (p < 0,001), estadio clínico (p < 0,001), Gleason en la biopsia prostática (p = 0,004), grupos de riesgo de D’Amico (p < 0,001), estadio patológico (p < 0,001) y porcentaje de pacientes con afectación ganglionar (p < 0,001). No obstante, no se detectan diferencias de significación estadística en el Gleason del espécimen de prostatectomía (p = 0,06) y en el porcentaje de márgenes quirúrgicos (p = 0,6). Conclusiones: Este estudio analiza una muestra amplia de pacientes procedente de toda la geografía española y presenta algunos datos importantes que reflejan la evolución que ha sufrido el cáncer de próstata localizado, tanto en lo que respecta al diagnóstico como al pronóstico, en nuestro país en los últimos 20 años (AU)

Objective: To know the changes that there has experienced the profile of patient candidate to prostatectomía radically throughout last 2 decades in our institution. Material and methods: We analyze retrospectively a series of 1.132 patients with prostate cancer stadium T1-T2, submitted to radical prostatectomy during the period 1989-2009. The series divides in five homogeneous groups as for the number of patients and arranged chronologically. There uses the free survival of biochemical progression (SLPB) as criterion principal forecast. Results: In spite of the changes in the diagnosis and treatment of the disease, from the point of view of the forecast (SLPB) we estimate two groups different from patients: the first 250 controlled ones and the rest. The point of chronological cut places in this series in 1.999. We find significant differences in the majority of the clinical - pathological variables as PSA's level to the diagnosis (P <0,001), percentage of palpable tumors (P <0,001), clinical stadium (P <0,001), Gleason in the prostate biopsy (P =0,004), groups at risk of D’Amico (P <0,001), pathological stadium (P <0,001) and percentage of patients mincingly ganglionar (P <0,001). Nevertheless, there are not detected differences of statistical significance in the Gleason of the specimen of prostatectomy (P =0,06) and in the percentage of surgical margins (P =0,6). Conclusions: This study analyzes a patients’ wide proceeding sample from the whole Spanish geography and presents some important information that reflect the evolution that has suffered the cancer of prostate located, so much regarding the diagnosis as to the forecast, in our country in the last 20 years (AU)

[Malignant priapism: conservative management of a case]. / Priapismo maligno: un caso manejado de forma conservadora.

Priapism is an urological emergency which requires investigation, especially to differentiate between ischemic and non-ischemic priapism. Initial management is carried out through aspiration and gasometry of blood from the corpus cavernosum. We report the case of a 69-year-old patient with urothelium carcinoma of the bladder T2 G3 and metastasis in urethra/corpus cavernosum who requested an emergency consultation because of edema and a penile erection lasting several days. Due to the poor prognosis and the imaging test, a conservative management was carried out.

Priapismo maligno: un caso manejado de forma conservadora / Malignant priapism: conservative management of a case

El priapismo es una urgencia urológica que requiere especial valoración, especialmente en la diferenciación de priapismo isquémico y no isquémico. El manejo inicial es mediante aspiración y gasometría de la sangre de los cuerpos cavernosos. Presentamos un paciente de 69 años diagnosticado de carcinoma de urotelio vesical T2, con metástasis en uretra/cuerpo cavernoso que acude a urgencias por edema y tumefacción peneano de varios días de evolución. Ante el pronóstico malo y las pruebas de imagen realizadas se decide tratamiento de soporte y quimioterápico (AU)

Priapism is an urological emergency which requires investigation, especially to differentiate between ischemic and non-ischemic priapism. Initial management is carried out through aspiration and gasometry of blood from the corpus cavernosum. We report the case of a 69-year-old patient with urothelium carcinoma of the bladder T2 G3 and metastasis in urethra/corpus cavernosum who requested an emergency consultation because of edema and a penile erection lasting several days. Due to the poor prognosis and the imaging test, a conservative management was carried out (AU)

Course of the type of patient who is candidate for radical prostatectomy over 2 decades (1989-2009).

OBJECTIVE: To know the changes experienced by the patient profile candidate for radical prostatectomy over the last 2 decades in our institution.. MATERIAL AND METHODS: We analyze retrospectively a series of 1.132 patients with prostate cancer stadium T1-T2, submitted to radical prostatectomy during the period 1989-2009. The series divides in five homogeneous groups as for the number of patients and arranged chronologically. There uses the free survival of biochemical progression (SLPB) as criterion principal forecast. RESULTS: In spite of the changes in the diagnosis and treatment of the disease, from the point of view of the forecast (SLPB) we estimate two groups different from patients: the first 250 controlled ones and the rest. The point of chronological cut places in this series in 1.999. We find significant differences in the majority of the clinical-pathological variables as PSA's level to the diagnosis (P <0,001), percentage of palpable tumors (P <0,001), clinical stadium (P <0,001), Gleason in the prostate biopsy (P =0,004), groups at risk of D'Amico (P <0,001), pathological stage (P <0,001), and percentage of patients with lymph node (P <0,001). Nevertheless, there are not detected differences of statistical significance in the Gleason of the specimen of prostatectomy (P =0,06) and in the percentage of surgical margins (P =0,6). CONCLUSIONS: This study analyzes a patients' wide proceeding sample from the whole Spanish geography and presents some important information that reflect the evolution that has suffered the cancer of prostate located, so much regarding the diagnosis as to the forecast, in our country in the last 20 years.

Perforación duodenal espontánea en paciente intervenido de prostatectomía radical / Spontaneous duodenal perforation in a radical prostatectomy patient

La prostatectomía radical es una cirugía para el cáncer localizado de próstata, muy conocida y con escaso número de complicaciones precoces postoperatorias. Presentamos el caso de un paciente de 54 años con PSA de 8 ng/ml y biopsia informada como adenocarcinoma de próstata Gleason 3+3=6 intervenido quirúrgicamente mediante prostatectomía radical retropúbica, que presentó una perforación espontánea de duodeno. Se manejó de forma conservadora ante el buen estado del paciente, resolviéndose a los 30 días. Ante un paciente intervenido es importante pensaren todas posibles complicaciones realizando las mínimas pruebas necesarias que permitan un diagnostico certero. El tratamiento habitualmente es quirúrgico, pudiéndose optar por el conservador en casos concretos(AU)

Radical prostatectomy is a well known treatment for prostate cancer, with a low incidence of early postoperative complications. Our case is a 54 year old patient diagnosed with prostate adenocarcinoma, Gleason score 3+3=6 with 8ng/ml of PSA, treated by retropubic prostatectomy, who suffered spontaneous perforation of the duodenum. We chose a conservative management, resolved in 30 days. When dealing with a surgical patient all kinds of complications must be taken into account by performing the minimum tests that will enable a sure diagnosis to be achieved. The usual treatment is surgery or conservative management, depending on the case and the patient(AU)

[Spontaneous duodenal perforation in a radical prostatectomy patient]. / Perforación duodenal espontánea en paciente intervenido de prostatectomía radical.

Radical prostatectomy is a well known treatment for prostate cancer, with a low incidence of early postoperative complications. Our case is a 54 year old patient diagnosed with prostate adenocarcinoma, Gleason score 3+3=6 with 8 ng/ml of PSA, treated by retropubic prostatectomy, who suffered spontaneous perforation of the duodenum. We chose a conservative management, resolved in 30 days. When dealing with a surgical patient all kinds of complications must be taken into account by performing the minimum tests that will enable a sure diagnosis to be achieved. The usual treatment is surgery or conservative management, depending on the case and the patient.